Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 17 min 33 sec ago

Veracyte Announces New Data Highlighting Performance of the Afirma GSC Ensemble Machine Learning Algorithms in Challenging Thyroid Cancer Subtypes to Be Presented at ATA

Sat, 21/10/2017 - 19:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (NASDAQ: VCYT) announced that data presented today at the 87th Annual Meeting of the American Thyroid Association (ATA) being held October 18-22 in Victoria, BC, Canada show that the Afirma Genomic Sequencing Classifier’s (GSC) ensemble machine learning algorithms can effectively distinguish challenging-to-interpret thyroid cancer subtypes among thyroid nodules deemed indeterminate – not clearly benign or malignant – by cytopathology.

Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome

Fri, 20/10/2017 - 09:00
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia) today announced plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD). Additionally, Aurinia announced plans to evaluate its proprietary nanomicellar voclosporin ophthalmic solution (VOS) for the treatment of keratoconjunctivitis sicca or dry eye syndrome (DES). The advancement of these new indications, in a

Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue Partnering Discussions

Fri, 20/10/2017 - 08:00
TORONTO--(BUSINESS WIRE)--ANTIBE THERAPEUTICS TO ATTEND 2017 CPHI WORLDWIDE CONFERENCE TO CONTINUE PARTNERING DISCUSSIONS

Cerveau Technologies, Inc. Signs Research Agreement with Columbia University Medical Center

Thu, 19/10/2017 - 12:00
BOSTON--(BUSINESS WIRE)--Cerveau Technologies Inc. today announced an agreement with Columbia University Medical Center in New York, New York to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodeg

Alzheimer’s Team Receives Highest Honors at Annual XPRIZE Visioneers Summit

Thu, 19/10/2017 - 10:00
WASHINGTON & SAN FRANCISCO--(BUSINESS WIRE)--A world-class team of scientists and advocates frustrated by the inadequacy in the global scope, urgency and funding to address the massive Alzheimer’s epidemic, and the slow pace of science, joined forces and received the highest honors at the 2017 XPRIZE Visioneers Summit. The team’s bold impact proposal is designed to globally crowdsource a new 21st century approach to diagnose, treat, cure and prevent the disease. XPRIZE, a non-profit and the glo

New BioBenefitsTM Program Allows Canadian Biotech Companies Access to Affordable Employee Benefits

Wed, 18/10/2017 - 10:00
OTTAWA, Ontario--(BUSINESS WIRE)--#EmployeeEngagement--BioTalent Canada partners with discount employee-benefits provider, BioBenefits, to help more Canadian biotechnology companies afford group benefits.

Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach

Wed, 18/10/2017 - 08:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) confirms its comprehensive approach to tackle MS at the seventh joint meeting of ECTRIMS/ACTRIMS.

Attune Medical Closes $10 Million Series C Financing To Support Continued Global Adoption of Esophageal Temperature Management Device

Tue, 17/10/2017 - 11:00
CHICAGO--(BUSINESS WIRE)--Breakthrough medical device firm Attune Medical has closed a $10 million Series C financing.

Acerus Announces Licensing of NATESTO® in South East Asian Countries

Tue, 17/10/2017 - 08:00
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the signing of an agreement granting Eu Hwa Pte LTD. (“EU”) the exclusive right to market NATESTO® in Thailand, Malaysia/Brunei, Singapore, Vietnam, Philippines, Hong Kong/Macau and one other small South East Asian country. EU is a subsidiary of one of Taiwan’s largest pharmaceutical companies, which has more than 800 employees worldwide as well as more than 300 dedicated pharmaceutical commercial employees w

AstraZeneca and Chi-Med’s Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification

Mon, 16/10/2017 - 19:00
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca and its partner Chi-Med today presented preliminary safety and clinical activity of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Phase Ib trials conducted in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with MET-amplification who had progressed following 1st-line treatment with an EGFR inhibitor.1,2 In both trials, the addition o

Cerveau Technologies Inc. Signs Collaboration Agreement with Janssen for Novel Tau Imaging Agent

Mon, 16/10/2017 - 15:00
BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with Janssen Pharmaceuticals, Inc. for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, which are made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. The collaboration is f

Canadian Biotech Industry Recognizes Top Performers

Mon, 16/10/2017 - 14:00
OTTAWA--(BUSINESS WIRE)--BIOTECanada announces winners of the prestigious 2017 Gold Leaf Awards, which recognize biotechnology excellence. Launched in 2001, the Gold Leaf awards are given annually to recognize both companies and individuals who have made significant contributions to the biotech industry in Canada. The Awards’ importance to the recipients and the industry more broadly has grown significantly over the years. “These remarkable individuals and companies serve to demonstrate the val

Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research

Mon, 16/10/2017 - 09:00
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today announced the second round of recipients of its HIV cure grants program. This new commitment will provide $7.5 million to support five additional HIV cure research initiatives led by top academic institutions and focused on translational research and efficacy studies in preclinical models. “Finding a cure for HIV is a formidable challenge to the scientific community. Together with our newest grant recipients, all of

Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIGTM (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer

Mon, 16/10/2017 - 03:00
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that data from the pivotal Phase 2 ALTA (ALK in Lung Cancer Trial of AP26113) clinical trial evaluating ALUNBRIGTM (brigatinib) in patients with locally advanced or metastatic anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who have progressed on crizotinib will be presented in an oral session at the International Association for the Study of Lung Can

FASLODEX (FULVESTRANT) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB1

Fri, 13/10/2017 - 14:00
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for Faslodex (fulvestrant) that will expand its use to include combination therapy with palbociclib.1 The combination use is for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic bre

MedX Health and Calian’s Primacy Management Join Together to Provide On-the-Spot Suspicious Mole and Lesion Scans at the Melanoma Network of Canada’s “Strides for Melanoma Walk for Awareness” Fundraiser

Thu, 12/10/2017 - 11:00
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX”) (TSX-V: MDX) notes that despite unusually sweltering heat in Toronto, hundreds of people participated in the Strides for Melanoma Walk for Awareness on Sunday, September 24 in Sunnybrook Park. The annual event, which included concurrent 5Km walks in cities across Canada, is a key fundraiser organized by the Melanoma Network of Canada (“MNC”), a national skin cancer patient advocacy and educational network. The MNC is collaboratin

Aurinia Receives National Corporate Visionary Award from the Lupus Foundation of America

Thu, 12/10/2017 - 08:00
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced it has received this year’s National Corporate Visionary Award from the Lupus Foundation of America. The award was presented to Dr. Richard and Michelle Glickman and to Aurinia for its long-term commitment to advancing treatments for lupus and lupus nephritis. The award was presented yesterday evening during the Foundation’s Annual Evening of Hope Gala in New York City. “We are h

Vince & Associates, an Altasciences Company, to Evaluate Marijuana Compound in Clinical Trial

Wed, 11/10/2017 - 10:00
OVERLAND PARK, Kan.--(BUSINESS WIRE)--#FDA--Vince & Associates will conduct an inpatient clinical trial on the psychological effects of an active ingredient in marijuana — cannabidiol — in support of a federal collaboration seeking to better understand the abuse potential of the substance. Vince & Associates was awarded a research subcontract valued at $2.8 million from Leidos Biomedical Research Inc., prime contractor for the government-sponsored Frederick National Laboratory for Cancer Rese

Centre for Contact Lens Research (CCLR) Renamed Centre for Ocular Research & Education (CORE)

Wed, 11/10/2017 - 10:00
CHICAGO--(BUSINESS WIRE)--#bioscience--The Centre for Contact Lens Research (CCLR) is being renamed the Centre for Ocular Research & Education (CORE), reflecting its evolved services.

Kalytera Therapeutics, Inc. Announces Robert Farrell, J.D. as CEO; Additional Board and Management Changes

Tue, 10/10/2017 - 20:00
SAN FRANCISCO & TEL AVIV, Israel--(BUSINESS WIRE)--Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") is pleased to announce that Robert Farrell, J.D., has been appointed as the Company's Chief Executive Officer ("CEO"). Mr. Farrell previously held the position of Interim CEO. Mr. Farrell has more than 25 years of experience in the pharmaceutical, biotechnology and medical device sectors. Prior to joining Kalytera, Mr. Farrell worked as an executive o

Pages